Today on Drug Discovery & Development
A merged AstraZeneca and BMS could lead Lilly on revenue until about 2030
In a potential marriage that analysts said faces long odds, AstraZeneca and Bristol Myers Squibb have held talks on a merger that would create the world’s largest drugmaker by revenue and rank among the biggest deals in pharmaceutical history, the Financial Times reported. The merger would also mark the most significant reshaping of pharma’s top…
AAPS PharmSci 360 to feature U.S. Pharmacopeia sessions
AAPS and the United States Pharmacopeia (USP) will again collaborate at the 2026 PharmSci 360 conference, scheduled for October 25-28 in New Orleans at the Ernest N. Morial Convention Center. USP has had a presence at recent meetings, including exhibit-hall stage sessions in 2025 and a talk on excipient and raw material grades in 2023.…
Drug Discovery and Development See More >
Sai Life Sciences’ bet on information-dense scale-up and how it is responding to pharma clients who want acceleration
Why has it taken so long, historically, to bring a new drug to market? In a word: complexity. At one end of the spectrum, there is the complexity of disease, genetic variability, the presence of environmental variables that cause patients to respond differently to the same treatment. The thread extends into clinical development, where the…
Ahead of PharmSci 360, DigiM CEO on turning hidden microstructures into drug-release predictions
CEO of CDMO AustinPx on its exclusive agreement with Thermo Fisher’s Patheon division
Top pharma companies set sustainability goals, but emissions are still increasing
SLAS 2026: Orchestration patforms, API-first instruments and the rise of semiautonomous labs
Sponsored Content See More >
Top Automated Dispensing Cabinets for Pharmacies: Leading Brands ComparedSimplifying workflows is essential. Individuals in the pharmacy industry may accomplish more work with fewer errors by automating medication distribution.…
How Endogenous Tagging is Reshaping Protein AnalysisUnderstanding how proteins behave inside living cells is essential for modern drug discovery. Yet many widely used approaches, particularly plasmid…
What sets oncology biosimilars apart: Anticipating key challenges in the development landscapeBy Kimberly Salgado, ICON plc Advancements in biologic therapies have greatly improved our ability to treat cancer over the last…
Advancing Pressure Protection in Biopharma: How Integrated Bypass Technology Elevates Single-Use Pump Designby Michael Irving, Xylem In pharmaceutical and biopharmaceutical manufacturing, there is zero margin for error when it comes to process…
Complexity’s counterpoint: Understanding protocol optimization In recent years, the clinical research landscape has been marked by a steady rise in protocol complexity with more endpoints…
Optimizing Data Pipelines in Life Sciences with AI-Driven Integration and FHIRSponsored by Infor. Data management in life sciences is inherently complex. Data is fragmented across multiple systems — such…
Accelerating life sciences with AI This case study is sponsored by Infor. Artificial intelligence can revolutionize clinical interoperability by building bridges across data silos. Machine…
Advancing Clinical Trials and ResearchThis case study is sponsored by Infor. In the complex landscape of clinical trials and medical research, data fragmentation remains…
Multidisciplinary approaches optimize contract drug discovery
5 Key Questions in Conducting Global Usability StudiesBy Dr Bryce G Rutter, Head Noble Consulting Services Evaluating device usability throughout the product development process is crucial. A…
Leveraging HF/UX/ID Services to Optimize the Design of Combination Devices for Arthritic HandsBy Dr. Bryce G Rutter, Head of Consulting Services Arthritis changes how people grasp and manipulate an object, reducing the…
Ask the Expert: Navigating the New FDA Rules on Laboratory Developed Tests (LDTs)The U.S. FDA released a final rule to regulate laboratory developed tests (LDTs) on May 6, 2024, making it clear…
Genomics/Proteomics See More >
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
“I remember when we decided the internet was going to cure everything, and it didn’t…it came with a certain set of problems,” said Mark Bagnall, CEO of Phenomix Sciences. GLP-1s are having a similar moment, he says. GLP-1s have been transformative for many; by 2025, more than 30 million Americans were taking them for weight…
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
Infectious Disease See More >
AbbVie’s Maviret ends the wait-and-see reality for acute HCV
AbbVie’s Maviret, known as Mavyret (glecaprevir/pibrentasvir) in the U.S., just became the only therapy approved in the EU for both acute and chronic hepatitis C virus (HCV), removing the need to confirm chronicity before treatment. While 2020 clinical guidance already recommended prompt treatment for acute HCV, the drug’s previous chronic-only indication could still lead to additional documentation, reimbursement hurdles or delays.The expanded indication brings the drug’s approved use in line with existing clinical recommendations. “We no longer have…
Oncology See More >
As chemo overtreatment comes into focus, Atossa bets on tamoxifen’s active form
As evidence mounts that some hormone receptor-positive, HER2-negative breast cancer patients are being overtreated with chemotherapy, researchers are working to identify which patients can safely avoid it, and to expand the treatment options available to those who can. Atossa Therapeutics thinks endoxifen, the active metabolite behind tamoxifen, could be an important addition to that toolkit. …
How ConcertAI turned CancerLinQ into a point-of-care oncology intelligence platform
Moderna bets on mRNA’s second act with cancer, autoimmune programs and AI research platform
Calderasib’s real innovation: designed for combinability and potency
